Ocuphire Pharma: Funding, Investors & Team (Sep 2026)
Ocuphire Pharma is a clinical-stage biopharmaceutical company focuses on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders. It is currently focused on providing a novel once-daily eye drop treatment option, Nyxol, to treat multiple front-of-the-eye disorders, including night vision disturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia. Nyxol eye drops are an investigational 505(b)(2) drug candidate in late-stage clinical development with over a decade of safety and efficacy data from Phase 1 and 2 trials. Part of their strategy is to explore opportunities to acquire additional ophthalmic assets for both the front and the back of the eyes and to seek strategic partners for global commercialization. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.
Ocuphire Pharma has raised $35.0M across 2 funding rounds on record, the most recent an undisclosed round of $20.0M announced in Mar 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Ocuphire Pharma Company Profile and Key Stats
Latest funding round on record: Mar 2025.
Ocuphire Pharma Funding Rounds
Ocuphire Pharma raised $15.0M in an undisclosed round announced in Jun 2021.
3.8 years later, an undisclosed round of $20.0M was announced in Mar 2025.
Ocuphire Pharma Founders and Leadership Team
Contact details for the Ocuphire Pharma team: 1 of 2 have an email address on file.
Start 14-day free trial →Ocuphire Pharma Funding Compared to Other Biotechnology Startups
Ocuphire Pharma's latest round of $20.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Ocuphire Pharma in Biotechnology and Farmington Hills
Companies Similar to Ocuphire Pharma
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Ocuphire Pharma Funding FAQs
What does Ocuphire Pharma do?
Ocuphire Pharma is a clinical-stage biopharmaceutical company focuses on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders. It is currently focused on providing a novel once-daily eye drop treatment option, Nyxol, to treat multiple front-of-the-eye disorders, including night vision disturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia. Nyxol eye drops are an investigational 505(b)(2) drug candidate in late-stage clinical development with over a decade of safety and efficacy data from Phase 1 and 2 trials. Part of their strategy is to explore opportunities to acquire additional ophthalmic assets for both the front and the back of the eyes and to seek strategic partners for global commercialization. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.
How much funding has Ocuphire Pharma raised?
Ocuphire Pharma has raised $35.0M across 2 rounds on record. The most recent is an undisclosed round of $20.0M announced in Mar 2025.
When did Ocuphire Pharma last raise funding?
Ocuphire Pharma's most recent funding round on record is an undisclosed round of $20.0M, announced in Mar 2025.
Who founded Ocuphire Pharma?
FundedIQ lists Alan Meyer (Founder) at Ocuphire Pharma.
Who is the CEO of Ocuphire Pharma?
Mina Sooch is listed as CEO at Ocuphire Pharma.
Where is Ocuphire Pharma headquartered?
Ocuphire Pharma is based in Farmington Hills, Michigan, United States.
How many employees does Ocuphire Pharma have?
Ocuphire Pharma is in the 11-50 employee band.
How does Ocuphire Pharma's funding compare to other Biotechnology startups?
Ocuphire Pharma's latest round of $20.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Ocuphire Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Ocuphire Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.